Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBTXR3 and Keytruda for Recurrent Head and Neck Cancer
NCT04834349Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2021
- Primary completion
- Nov 2022
01
Overview
A Phase 2 trial of NBTXR3 in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Mar 2021; status: withdrawn.
02
Drugs
NBTXR3
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04834349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04834349.